Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva - LARVOL DELTA

Impact of pharmacotherapy with inhaled corticosteroids and long-acting beta-2 agonists on symptom control and oscillometry parameters among Indian patients with early COPD due to smoking and non-smoking causes: indian pre COPD assessment network (IeCAN) study (BTS WM 2025) - "Participants underwent HRCT, received salbutamol inhaler as needed and randomized to once-daily Fluticasone Furoate/Vilanterol or placebo...Pre-COPD can potentially be defined in at risk patients with normal spirometry if they have CAT>10 and Ax>10. A larger study is needed to assess whether these findings are reproducible and generalisable."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases • Tobacco Cessation

The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on…costly prescription drugs under Medicare… (MSN News) - "Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price:...(i) Trelegy Ellipta, an asthma treatment: $175, down from $654...; (ii) Ofev, for idiopathic pulmonary fibrosis: $6,350, down from $12,622...; (iii) Breo Ellipta, a COPD drug: $67, down from $397."

Commercial • Asthma • Chronic Obstructive Pulmonary Disease • Idiopathic Pulmonary Fibrosis

Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma (clinicaltrials.gov) - P3 | N=1430 | Not yet recruiting | Sponsor: Sandoz

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Effectiveness of indacaterol/glycopyrronium/mometasone for refractory asthmatic cough after switching from inhaled corticosteroid/long-acting β2-agonist therapy. (PubMed, J Allergy Clin Immunol Glob) - "In this multicenter, randomized, open-label, parallel-group study, 118 patients were randomized to receive either IND/GLY/MF or high-dose ICS/LABA (fluticasone/vilanterol [FF/VI] or budesonide/formoterol [BUD/FM]) for 8 weeks. Symptoms improved comparably between medium-dose IND/GLY/MF and high-dose ICS/LABA combinations, although no superiority could be demonstrated. Medium-dose IND/GLY/MF may be an alternative to high-dose ICS/LABA."

Journal • Asthma • Cough • Immunology • Pulmonary Disease • Respiratory Diseases

UNEXPECTED PULMONARY FINDINGS IN A TRAVELER: A CASE OF LATENT TUBERCULOSIS IN AN ELDERLY PATIENT (CHEST 2025) - "was diagnosed with acute bronchitis and treated with albuterol and azithromycin, leading to symptom improvement...He was prescribed intranasal fluticasone, fluticasone/vilanterol inhaler, and tessalon perles, which resolved his symptoms... This case features the importance of screening for LTBI in elderly patients with new-onset pulmonary abnormalities, even if prior TB tests were negative. It emphasizes the increasing role of CT imaging in spotting asymptomatic pulmonary abnormalities that might need further investigation. A multidisciplinary approach is crucial for accurate diagnosis and management."

Clinical • Chronic Cough • Cough • Immunology • Infectious Disease • Mood Disorders • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Comparative Effectiveness of Fixed-Dose ICS/LABA Therapy in Adult Patients with Asthma. (PubMed, Ann Allergy Asthma Immunol) - "The findings suggest that fluticasone furoate/vilanterol may offer a potential advantage for asthma management compared to other fixed-dose ICS/LABA combinations."

HEOR • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

The Combined Impact of Omalizumab and Allergen Immunotherapy (AIT) in Severe Asthma. (ERS 2025) - " Three women (mean age: 23) with childhood-onset asthma previously treated with inhaled corticosteroid and long- acting beta-2 agonist (fluticasone furoate/vilanterol, 184/22 mcg once daily), tiotropium bromide (5 mcg once daily), montelukast and nasal corticosteroids. Omalizumab pre-treatment improves symptom control and facilitates AIT implementation. In this series of patients, combination therapy increased efficacy, reduced drug use and sustained asthma control even after omalizumab discontinuation."

Asthma • Immunology • Respiratory Diseases

Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/Formoterol Fumarate in General Practice in England. (PubMed, Adv Ther) - "Overall, patients initiating FF/VI and BDP/FOR had numerically similar exacerbation rates; of the patients continuing 12 months' uninterrupted treatment, the FF/VI group had a lower exacerbation rate versus BDP/FOR. Patients initiating FF/VI were less likely to discontinue treatment than those initiating BDP/FOR."

HEOR • Journal • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Causal machine learning to investigate heterogeneity in time to first COPD exacerbation for ICS/LABA versus LAMA/LABA (ERS 2025) - P3 | "Background and aim: In the IMPACT trial (NCT02164513), a comparison of the two control arms shows on average no benefit of fluticasone furoate/vilanterol (FF/V, ICS/LABA) over umeclidinium/vilanterol (U/V, LAMA/LABA) in time to first COPD exacerbation (hazard ratio (HR) 0.98, p=0.5). This use case highlights how specific patient profiles may benefit from different treatments, even if on average no effect is observed. Causal ML is a promising tool to uncover such patterns in data from randomized controlled trials."

Heterogeneity • Machine learning • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Real-world evidence (RWE) study on clinical outcomes in asthma: fluticasone furoate/vilanterol (FF/VI) versus (vs) budesonide/formoterol (BUD/FOR) (ERS 2025) - "Results Exacerbation rate for FF/VI was numerically similar vs BUD/FOR in the patient population on initiated treatment 2 , lower in the population when outcome was measured until an event1, and significantly lower among patients who continued uninterrupted treatment for 1 year 3 (FF/VI n=425; BUD/FOR n=546; Table ). Conclusion Patients on FF/VI had fewer exacerbations vs those on BUD/FOR after uninterrupted treatment for 1 year."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Real-world evidence (RWE): asthma clinical-outcomes, fluticasone furoate/vilanterol (FF/VI) versus (vs) beclometasone dipropionate/formoterol (BDP/FOR) (ERS 2025) - "Results Patients initiated on FF/VI had a numerically similar exacerbation rate vs BDP/FOR in the patient population on initiated treatment 2 , lower in the population when outcome was measured till an event 1 , and significantly lower among patients continuing treatment for 1 year without interruption 3 (FF/VI [n=384] vs BDP/FOR [n=3342]; Table ). Conclusion After uninterrupted treatment for 1 year, FF/VI was associated with fewer exacerbations vs BDP/FOR."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Real-world Comparative Effectiveness in Patients with Asthma Newly Initiating Fluticasone Furoate/Vilanterol or Budesonide/Formoterol: A United Kingdom General Practice Cohort Study. (PubMed, Pulm Ther) - "Patients who continued initiation treatment for a year without interruption had reduced exacerbation rates with FF/VI versus BUD/FOR. The FF/VI group also had reduced treatment discontinuation and OCS use."

HEOR • Journal • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Single-inhaler triple therapy improves small airway dysfunction in moderate to severe asthma and asthma-COPD overlap: a retrospective cohort study. (PubMed, J Asthma) - "Medium- or high-dose fluticasone furoate (FF)/vilanterol (VI)/umeclidinium (UMEC) is associated with an improvement in forced expiratory volume in one second (FEV1), a marker of large airway dysfunction. Improvements in FEV1, X5, and AX correlated with improvements in ACT, and improvements in FEV1 and FEV1/FVC correlated with improvements in ACQ. FF/VI/UMEC improved SAD, and its improvement was correlated with improved asthma control in moderate to severe asthma and ACO patients."

Journal • Retrospective data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Abnormal Lung Infections in an Immunocompetent Patient - Middle Lobe Syndrome (ATS 2025) - "She was switched from fluticasone/vilanterol inhaler to beclomethasone dipropionate and fluticasone/umeclidinium/vilanterol inhalers and underwent pulmonary function testing and chest CT...She was restarted on levofloxacin for a prolonged course and scheduled for bronchoscopy...She underwent balloon dilation and dexamethasone injection of the RML...In this patient, she had a documented history of collapse but was otherwise treated for asthma for 6 years before transferring her care to a tertiary care center. As with all treatment resistant patients, revisiting their original diagnosis may reveal a separate clinical entity that can warrant radical change to treatment plan."

Clinical • Asthma • Chronic Cough • Cough • Fibrosis • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Finding the Best Fit: A Head-To-Head Comparison of Triple Therapy Regimens in COPD (ATS 2025) - "This study evaluates the efficacy of two triple therapy regimens — Glycopyrrolate, Budesonide, and Formoterol Fumarate (GLY/BUD/FOR) and Fluticasone Furoate, Vilanterol, and Umeclidinium (FF/VI/UMEC) —in adults aged 45 and older with diagnosed COPD with FEV1/FVC < 70% to assess the impact of these regimens on the preventing COPD exacerbations and acute hypoxemic respiratory failure. Our study suggests that FF/VI/UMEC demonstrated an increased risk of COPD exacerbations and acute hypoxic respiratory failure compared to the group receiving GLY/BUD/FOR. This indicates that GLY/BUD/FOR may provide enhanced protective benefits in patients with moderate to severe COPD, improving disease management and minimizing healthcare resource utilization. Further studies are warranted to explore the long-term benefits and potential mechanisms underlying the observed differences."

Head-to-Head • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Heart Failure • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases

Economic Evaluation of Single-Inhaler Extrafine Beclometasone Dipropionate/formoterol fumarate/glycopyrronium (Trimbow®) in Adult Patients with Uncontrolled Asthma in Mexico (ISPOR 2025) - "The annual per-patient cost for BDP/FF/G was $3,881.34, compared to Beclometasone/Formoterol ($4,373.36), Budesonide/Formoterol ($6,098.29), Salmeterol/Fluticasone ($14,014.57), and Fluticasone/Vilanterol ($14,096.49). The extrafine SITT with BDP/FF/G is a dominant therapeutic option for adults with uncontrolled asthma in Mexico, delivering superior asthma control, significantly reducing exacerbations, and lowering annual per-patient costs compared to therapies currently used by IMSS."

Clinical • HEOR • Asthma • Immunology • Respiratory Diseases

COPD in elderly patients (PubMed, Pneumologie) - "Substances with a long duration of action, such as fluticasone furoate, vilanterol and umeclidinium, are the best option. This is due to the increase in occlusion capacity, which causes the small airways to collapse earlier. It is essential to consider comorbidities and body position during blood gas sampling to avoid an oversupply of home oxygen therapy in old age."

Journal • Alzheimer's Disease • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Congestive Heart Failure • Dementia • Gastrointestinal Disorder • Geriatric Disorders • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases • Sarcopenia

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma (clinicaltrials.gov) - P3 | N=356 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients. (PubMed, Respir Med) - "Exacerbating patients had lower lung doses (28.8±5.8% for Foster® NEXThaler® and 23.7±3.8% for Relvar® Ellipta®) than their non-exacerbating counterparts (33.7±6.1% for Foster® NEXThaler® and for 24.9±3.9% for Relvar® Ellipta®). The exact clinical consequences of the differences between the deposition distributions of the two drugs could be assessed only by systematic clinical trials."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A CASE OF IgG4-RELATED DISEASE WITH CONFIRMED RESPONSE TO DUPILUMAB BY SMALL SALIVARY GLAND BIOPSY (PubMed, Arerugi) - "Fluticasone-vilanterol was introduced, but there was little improvement in the cough. In addition, serum IgG4 levels decreased after the initiation of dupilumab treatment, and a decrease in IgG4-positive plasma cells was observed on small salivary gland biopsy. Thus, the treatment of inhaled steroid-resistant bronchial asthma with dupilumab can also improve IgG4-related disease, and we confirmed a decrease in IgG4-positive plasma cells in the small salivary glands."

Biopsy • Journal • Asthma • Cough • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • Small Intestinal Carcinoma

Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass. (PubMed, ERJ Open Res) - "The purpose of the study was to compare the efficacy of fluticasone furoate/vilanterol (FF/V) 100/25 μg and umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnoea, health-related quality of life (HRQL), forced expiratory volume in 1 s (FEV1) and inspiratory capacity (IC) during a period of 6 months in patients with COPD-B and COPD-C, at a third level referral centre in Mexico City. All groups showed improvement in dyspnoea and HRQL, independently of medication used. Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnoea and HRQL."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

In Vitro Analysis of Aerodynamic Properties and Co-Deposition of a Fixed-Dose Combination of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate. (PubMed, Pharmaceutics) - "Spatial distribution and abundance of ICS/LABA/LAMA in the same cascade levels were closely comparable, and the aerosol particles were able to reach the small aerosol-sized cascades at the lower levels to some extent."

Journal • Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Relation between treatable traits, treatment (Tx) choices and symptom control/exacerbation (exac) risk in moderate–severe asthma (ERS 2024) - "To mimic clinical practice, data from a 16000 pt-cohort were modelled to initiate on fluticasone propionate, then stepped-up to fluticasone furoate/vilanterol (FF/VI) or budesonide/formoterol (BUD/FOR) if symptoms were not well controlled (ACQ-5 ≥1.5) in 0.25yr...At 1yr, 81.1% and 75.7% of pts on FF/VI and BUD/FOR had ACQ-5 ≤1.5 (p<0.01), respectively. Conclusions ACQ-5/exac risk are modulated by pt characteristics (BMI, sex), asthma control, lung function and Tx, highlighting personalised asthma management importance."

Asthma • Immunology • Respiratory Diseases

Single-inhaler triple therapy improves small airway dysfunction in moderate to severe asthma. (ERS 2024) - " Subjects included 30 asthma patients who switched from ICS/LABA to SITT (fluticasone furoate/vilanterol/umeclinidium, mometasone/indacaterol/glycopyrronium, and budesonide/formoterol/glycopyrronium), with spirometry and oscillometry performed before and after switching... SITT improved SAD, and higher R5−R20 before SITT predicted responsiveness to SITT in moderate to severe asthma patients. Table. Multivariate logistic regression analyses for predicting responders to SITT Adjusted odds ratio 95% confidence interval P-value ACT 0.242 0.049 to 1.190 0.080 History of smoking 0.173 0.024 to 1.260 0.083 R5−R20(per 0.01 cmH2O/L/s) 1.130 1.010 to 1.260 0.037 Fres 0.526 0.2070 to 1.340 0.178"

Asthma • Immunology • Respiratory Diseases

Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate-Severe Asthma: A Clinical Modelling and Simulation Study. (PubMed, Adv Ther) - "This study provided further insight into the effects of individual baseline characteristics on treatment response and highlighted significant differences in the performance of ICS/LABA combination therapy on symptom control, reliever use and exacerbation risk. These factors should be incorporated into clinical practice as the basis for tailored management of patients with moderate-severe asthma."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases